These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 24903533)
1. Design, synthesis and evaluation of rhodanine derivatives as aldose reductase inhibitors. Agrawal YP; Agrawal MY; Gupta AK Chem Biol Drug Des; 2015 Feb; 85(2):172-80. PubMed ID: 24903533 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of new epalrestat analogues as aldose reductase inhibitors (ARIs). Reddy TN; Ravinder M; Bagul P; Ravikanti K; Bagul C; Nanubolu JB; Srinivas K; Banerjee SK; Rao VJ Eur J Med Chem; 2014 Jan; 71():53-66. PubMed ID: 24275248 [TBL] [Abstract][Full Text] [Related]
3. In vitro studies of potent aldose reductase inhibitors: Synthesis, characterization, biological evaluation and docking analysis of rhodanine-3-hippuric acid derivatives. Celestina SK; Sundaram K; Ravi S Bioorg Chem; 2020 Apr; 97():103640. PubMed ID: 32086051 [TBL] [Abstract][Full Text] [Related]
4. Quinazolinone-based rhodanine-3-acetic acids as potent aldose reductase inhibitors: Synthesis, functional evaluation and molecular modeling study. El-Sayed S; Metwally K; El-Shanawani AA; Abdel-Aziz LM; El-Rashedy AA; Soliman MES; Quattrini L; Coviello V; la Motta C Bioorg Med Chem Lett; 2017 Oct; 27(20):4760-4764. PubMed ID: 28935265 [TBL] [Abstract][Full Text] [Related]
5. (4-Oxo-2-thioxothiazolidin-3-yl)acetic acids as potent and selective aldose reductase inhibitors. Kucerova-Chlupacova M; Halakova D; Majekova M; Treml J; Stefek M; Soltesova Prnova M Chem Biol Interact; 2020 Dec; 332():109286. PubMed ID: 33038328 [TBL] [Abstract][Full Text] [Related]
6. Epalrestat, an Aldose Reductase Inhibitor Prevents Glucose-Induced Toxicity in Human Retinal Pigment Epithelial Cells In Vitro. Senthilkumari S; Sharmila R; Chidambaranathan G; Vanniarajan A J Ocul Pharmacol Ther; 2017; 33(1):34-41. PubMed ID: 27835059 [TBL] [Abstract][Full Text] [Related]
7. Docking and molecular dynamics studies toward the binding of new natural phenolic marine inhibitors and aldose reductase. Wang Z; Ling B; Zhang R; Suo Y; Liu Y; Yu Z; Liu C J Mol Graph Model; 2009 Sep; 28(2):162-9. PubMed ID: 19616461 [TBL] [Abstract][Full Text] [Related]
8. Ranirestat has a stronger inhibitory activity on aldose reductase and suppresses inflammatory reactions in high glucose-exposed endothelial cells. Ishibashi Y; Matsui T; Matsumoto T; Kato H; Yamagishi S Diab Vasc Dis Res; 2016 Jul; 13(4):312-5. PubMed ID: 27190083 [TBL] [Abstract][Full Text] [Related]
9. Novel synthesis of nitro-quinoxalinone derivatives as aldose reductase inhibitors. Hussain S; Parveen S; Qin X; Hao X; Zhang S; Chen X; Zhu C; Ma B Bioorg Med Chem Lett; 2014 May; 24(9):2086-9. PubMed ID: 24726808 [TBL] [Abstract][Full Text] [Related]
10. Novel rhodanine based inhibitors of aldose reductase of non-acidic nature with p-hydroxybenzylidene functional group. Kratky M; Sramel P; Bodo P; Prnova MS; Kovacikova L; Majekova M; Vinsova J; Stefek M Eur J Med Chem; 2023 Jan; 246():114922. PubMed ID: 36455357 [TBL] [Abstract][Full Text] [Related]
11. Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase. Lee YS; Chen Z; Kador PF Bioorg Med Chem; 1998 Oct; 6(10):1811-9. PubMed ID: 9839011 [TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships studies of quinoxalinone derivatives as aldose reductase inhibitors. Hussain S; Parveen S; Hao X; Zhang S; Wang W; Qin X; Yang Y; Chen X; Zhu S; Zhu C; Ma B Eur J Med Chem; 2014 Jun; 80():383-92. PubMed ID: 24793885 [TBL] [Abstract][Full Text] [Related]
13. Induced fit docking, pharmacophore modeling, and molecular dynamic simulations on thiazolidinedione derivatives to explore key interactions with Tyr48 in polyol pathway. Vijjulatha M; Lingala Y; Merugu RT J Mol Model; 2014 Jul; 20(7):2348. PubMed ID: 24974084 [TBL] [Abstract][Full Text] [Related]
14. Urinary sorbitol measurement and the effect of an aldose reductase inhibitor on its concentration in the diabetic state. Nakano I; Tsugawa T; Shinohara R; Watanabe F; Fujita T; Nagata M; Kato T; Himeno Y; Kobayashi T; Fujiwara K; Nagata M; Itoh M; Nagasaka A J Diabetes Complications; 2003; 17(6):337-42. PubMed ID: 14583178 [TBL] [Abstract][Full Text] [Related]